[www.umc.com Description 99.1 Announcement on 2018/08/20: Important Resolutions from UMC’s 2018 First Extraordinary General Meeting 99.2 Announcement on 2018/08/20: UMC’s 2018 First Extraordinary General Meeting has approved to release the Director from non-competition restrictions 1 Important Resolu]
[FORM 10−Q (Mark One) [X] For the quarterly period ended: June 30, 2018 [ ] For the transition period from _____________ to _____________ 001-32898 CBAK ENERGY TECHNOLOGY, INC. Nevada 88-0442833 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) BAK In]
[Studio City International Holdings Limited Provides an Update on Proposed Initial Public Offering Studio City IPO ADSs SEC MACAU, Aug. 20, 2018 Studio City International Holdings Limited ( Safe Harbor Statement For investment community, please contact: Richard Huang Director, Investor Relations T]
[Global Cord Blood Corporation Announces the Results of Scrip Dividend Elections HONG KONG, China, August 17 , 2018 - Global Cord Blood Corporation As a result of these elections, the Company will issue a total of 726,333 ordinary shares and consequently the Companys outstanding ordinary shares will]
[FORM 10−Q (Mark One) [X] For the quarterly period ended: June 30, 2018 [ ] For the transition period from _____________ to _____________ 001-32898 CBAK ENERGY TECHNOLOGY, INC. Nevada 88-0442833 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) BAK In]
[Studio City International Holdings Limited Provides an Update on Proposed Initial Public Offering Studio City IPO ADSs SEC MACAU, Aug. 20, 2018 Studio City International Holdings Limited ( Safe Harbor Statement For investment community, please contact: Richard Huang Director, Investor Relations T]
[Global Cord Blood Corporation Announces the Results of Scrip Dividend Elections HONG KONG, China, August 17 , 2018 - Global Cord Blood Corporation As a result of these elections, the Company will issue a total of 726,333 ordinary shares and consequently the Companys outstanding ordinary shares will]
[SEC Concludes Investigation of Sinovac About Sinovac Sinovac Biotech Ltd. is a China-based biopharmaceutical Company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccine]
[iKang Announces Shareholders Approval of Going Private Transaction Approximately 62.91% of the Companys total outstanding shares, representing approximately 71.92% of the voting rights of the Companys shares, voted in person or by proxy at the EGM. If the Merger is completed, the Company will b]
[1 Announcement dated August 17, 2018 in respect of Appointment of Executive Directors. build-out the Companys ability to effectively sustain its growth and to achieve or enhance profitability; changes in the PRC telecommunications industry resulting from the issuance of licenses for telecommu]
